Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PCI Biotech has concluded patient recruitment with the enrollment of last patient in a Phase I/II study of its lead candidate PC-A11 in cancer patients.
Subscribe to our email newsletter
The last patient has been treated with the company’s proprietary photosensitiser Amphinex used in combination with the cytotoxic agent bleomycin at University College Hospital (UCH) in London.
Principal investigator Colin Hopper said the results have been very positive, with strong tumour response in all the treated patients, and they look forward to take part in the further development of PC-A11 in the treatment of Head and Neck cancer patients.
PCI Biotech CEO Per Walday said the study has proved that we can transfer strong preclinical results to equally strong clinical results, and this is promising for the further development of PC-A11 and other combination products based on the PCI technology platform.